Richard H. Hughes, IV, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in The New York Times, in “An R.S.V. Shot for Infants Is in Short Supply. Here’s What to Know,” by Dana G. Smith. (Read the full version – subscription required.)

Following is an excerpt:

The drug, called nirsevimab and sold under the brand name Beyfortus, was approved by the Food and Drug Administration in July. The Centers for Disease Control and Prevention initially recommended that it be given to all infants who are less than 8 months old, and to children 8 to 19 months old who have an increased risk for severe R.S.V.

But the demand for nirsevimab has exceeded the supply — right as R.S.V. season has started to pick up. On Monday, the C.D.C. issued an alert about the drug’s limited availability and said doctors who currently have doses should prioritize babies who are at the highest risk for severe infections: those who are less than 6 months old and infants who are immunocompromised or have an underlying health condition, such as cystic fibrosis. ...

The shortage appears to be affecting both large hospitals and small health clinics. Whether a health care provider has nirsevimab in stock largely depends on when and how much they ordered, said Richard Hughes IV, a vaccine-law expert at the firm Epstein Becker Green. ...

The drug is what is known as a monoclonal antibody therapy. It works somewhat like a vaccine, providing protection against severe disease. But the protection lasts just a few months. That’s because instead of teaching the baby’s immune system to develop antibodies against the virus, the injection delivers those antibodies directly. But once the antibodies are gone, so is the protection.

Another monoclonal antibody therapy, palivizumab, was approved in 1998 to prevent severe R.S.V. It has historically been reserved for preterm infants — who have some of the highest risk — because the drug is expensive and must be injected monthly. With the shortage of nirsevimab, the C.D.C. is now recommending that high-risk infants between 8 and 19 months be given palivizumab instead. There is an exception for American Indian and Alaska Native children who live in remote areas and have limited access to health care; they should still be given nirsevimab, if available.

An alternative option also exists for expectant mothers: This summer, the F.D.A. approved an R.S.V. vaccine for people who are 32 to 36 weeks pregnant. The antibodies they develop in response to the vaccine are passed through the placenta to the fetus, so the infant is born with protection against R.S.V.

If you have a young child who does not meet the current C.D.C. guidelines for immunization, your pediatrician is your best resource. Contact them if your child has symptoms like severe coughing, wheezing or shortness of breath.

While the shortage can be frustrating for pediatricians and parents, some experts see it as a positive sign that demand for the immunization is so high. “I think this is a reflection of success,” Mr. Hughes said. “We have this brand-new tool to protect infants, and we’ve waited so long to be able to do that.”

Related Materials

The original article also appeared on The Baltimore Sun and Chicago Tribune (subscription required).

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.